文献速递胸部肿瘤

PD-L1评分作为亚洲早期表皮生长因子受体突变肺癌的预后生物标志物

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
PubMed 文献 · Eur J Cancer · 2022-10-20

本研究纳入新加坡国家癌症中心2010年1月1日至2019年12月31日诊断的455例IA-IIIA期非小细胞肺癌患者,比较EGFR突变型与野生型中PD-L1评分的预后价值。EGFR突变型中PD-L1≥1%与更差的无病生存和总生存相关,且为总生存的独立预测因素。

要点

  • EGFR突变型中PD-L1≥1%者2年无病生存67.6% vs PD-L1<1%者78.1%(p=0.007)。
  • EGFR突变型中PD-L1≥1%者5年总生存42.8% vs PD-L1<1%者59.5%(p=0.001)。
  • PD-L1≥1%是EGFR突变型早期NSCLC总生存的独立预测因素(HR 2.18,95%CI 1.04-4.54,p=0.038)。

核心结论

  • PD-L1≥1%是早期EGFR突变型NSCLC总生存更差的独立预测因素,并与无病生存更差相关,且该关联不受EGFR状态影响。
  • 作者认为PD-L1评分作为风险分层因素应在EGFR突变型NSCLC的前瞻性辅助治疗研究中评估。

研究设计与样本

  • 研究为连续纳入2010年1月1日至2019年12月31日在新加坡国家癌症中心诊断的IA-IIIA期NSCLC患者,要求EGFR和PD-L1状态可评估。
  • 共纳入455例患者,其中EGFR突变型267例,EGFR野生型188例。
  • 共同主要终点为采用Kaplan-Meier法计算的2年无病生存和5年总生存。

主要发现

  • 中位诊断年龄65岁,男性占52.3%(238/455),从不吸烟者占62.9%(286/455),R0切除占92.5%(421/455)。
  • 分期构成:IA期42.4%(193/455),IB期23.1%(105/455),IIA期10.8%(49/455),IIB期5.1%(23/455),IIIA期18.7%(85/455)。
  • EGFR突变型中Ex19del占45.3%(121/267),L858R占41.9%(112/267)。
  • EGFR突变型与野生型中PD-L1≥1%分别为45.3%(121/267)和54.8%(103/188)(p=0.047)。
  • 中位随访47个月时,178例患者复发。

关键数值与推荐

  • EGFR突变型中,PD-L1<1% vs PD-L1≥1%的2年无病生存分别为78.1%和67.6%(p=0.007)。
  • EGFR突变型中,PD-L1<1% vs PD-L1≥1%的5年总生存分别为59.5%和42.8%(p=0.001)。
  • 控制年龄、性别、淋巴血管侵犯、辅助治疗和切缘状态后,PD-L1≥1%(HR 2.18,95%CI 1.04-4.54,p=0.038)、IIB期(HR 7.78,95%CI 1.72-35.27,p=0.008)和IIIA期(HR 4.45,95%CI 1.44-13.80,p=0.01)为总生存更差的独立预测因素。
  • 探索性分析对81例EGFR突变型肿瘤进行基因组分析,PD-L1≥1%肿瘤的TP53突变率显著更高(36.1% vs 15.6%,p=0.04),且以错义突变为主。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To determine the prognostic value of programmed death-ligand 1 (PD-L1) score in early-stage epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), contrasted against EGFR-wildtype NSCLC. METHODS: Consecutive patients with Stage IA-IIIA NSCLC diagnosed 1st January 2010-31st December 2019 at National Cancer Centre Singapore with evaluable EGFR and PD-L1 status were included. Co-primary end-points were 2-year disease-free survival (DFS) and 5-year overall survival (OS) by Kaplan-Meier method. RESULTS: 455 patients were included (267 EGFR-mutated, EGFR-M+; 188 EGFR-wildtype, wt). Median age at diagnosis was 65 years, 52.3% (238/455) of patients were males, 62.9% (286/455) of patients were never-smokers and 92.5% (421/455) of patients had R0 resection. Stage IA comprised 42.4% (193/455) of patients, Stage IB comprised 23.1% (105/455) of patients, Stage IIA comprised 10.8% of patients (49/455), Stage IIB comprised 5.1% of patients (23/455) and Stage IIIA comprised 18.7% (85/455) of patients. Among EGFR-M+, 45.3% (121/267) were Ex19del and 41.9% (112/267) were L858R. PD-L1 ≥1% among EGFR-M+ and EGFR-wt was 45.3% (121/267) and 54.8% (103/188) respectively (p = 0.047). At median follow-up of 47 months, 178 patients had relapsed. Among EGFR-M+, 2-year DFS comparing PD-L1 <1% and PD-L1 ≥1% was 78.1% and 67.6% (p = 0.007) while 5-year OS was 59.5% and 42.8% (p = 0.001), respectively. Controlling for age, gender, lymphovascular invasion, adjuvant therapy and resection margin status, PD-L1 ≥1% (hazard ratio, HR 2.18, 95% CI 1.04-4.54, p = 0.038), stage IIB (HR 7.78, 95% CI 1.72-35.27, p = 0.008) and stage IIIA (HR 4.45, 95% CI 1.44-13.80, p = 0.01) emerged as independent predictors of inferior OS on multivariable analysis. In exploratory analysis, genomic analysis of 81 EGFR-M+ tumours was performed. PD-L1 ≥1% tumours had significantly higher rates of TP53 mutations (36.1% versus 15.6%, p = 0.04), with predominantly missense mutations. CONCLUSION: PD-L1 ≥1% is an independent predictor of worse OS among early-stage EGFR-mutated NSCLC and is associated with inferior DFS regardless of EGFR status. PD-L1 score as a risk stratification factor should be evaluated in prospective adjuvant studies among EGFR-mutated NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saw SPL, Ng WP, Zhou S, et al. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022. PMID: 36436331. doi:10.1016/j.ejca.2022.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。